Literature DB >> 26090645

Autosomal dominant polycystic kidney disease: the changing face of clinical management.

Albert C M Ong1, Olivier Devuyst2, Bertrand Knebelmann3, Gerd Walz4.   

Abstract

Autosomal dominant polycystic kidney disease is the most common inherited kidney disease and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although first reported 500 years ago, this disorder is still regarded as untreatable and its pathogenesis is poorly understood despite much study. During the past 40 years, however, remarkable advances have transformed our understanding of how the disease develops and have led to rapid changes in diagnosis, prognosis, and treatment, especially during the past decade. This Review will summarise the key findings, highlight recent developments, and look ahead to the changes in clinical practice that will likely arise from the adoption of a new management framework for this major kidney disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26090645     DOI: 10.1016/S0140-6736(15)60907-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  112 in total

1.  Editor's introduction--genetic polymorphisms and clinical heterogeneities.

Authors:  Martin Wilkie
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

Review 2.  Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hannah A Blair; Gillian M Keating
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

3.  Multiple unilateral subcapsular cortical hemorrhagic cystic disease of the kidney: CT and MRI findings and clinical characteristic.

Authors:  Kotaro Yoshida; Naoki Takahashi; Bernard F King; Akira Kawashima; Peter C Harris; Lynn D Cornell; Emilie Cornec-Le Gall; Dai Inoue; Ichiro Mizushima; Mitsuhiro Kawano; Eric Thervet; Paul René de Cotret; Vicente E Torres
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

4.  Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Rory J Olson; Whitney Besse; Christina M Heyer; Vladimir G Gainullin; Jessica M Smith; Marie-Pierre Audrézet; Katharina Hopp; Binu Porath; Beili Shi; Saurabh Baheti; Sarah R Senum; Jennifer Arroyo; Charles D Madsen; Claude Férec; Dominique Joly; François Jouret; Oussamah Fikri-Benbrahim; Christophe Charasse; Jean-Marie Coulibaly; Alan S Yu; Korosh Khalili; York Pei; Stefan Somlo; Yannick Le Meur; Vicente E Torres; Peter C Harris
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

5.  Hyponatremia and cyst growth in neonatal polycystic kidney disease: a case for aquaretics?

Authors:  Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2017-02-13       Impact factor: 3.714

6.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

Review 7.  The Treatment of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Wolfgang E Kühn; Gerd Walz
Journal:  Dtsch Arztebl Int       Date:  2015-12-21       Impact factor: 5.594

8.  Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Salim S Hayek; Douglas P Landsittel; Changli Wei; Martin Zeier; Alan S L Yu; Vicente E Torres; Sharin Roth; Christina S Pao; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2019-06-06       Impact factor: 10.121

9.  The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Authors:  Emilie Cornec-Le Gall; Fouad T Chebib; Charles D Madsen; Sarah R Senum; Christina M Heyer; Brendan C Lanpher; Marc C Patterson; Robert C Albright; Alan S Yu; Vicente E Torres; Peter C Harris
Journal:  Am J Kidney Dis       Date:  2018-02-01       Impact factor: 8.860

Review 10.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.